Edesa Biotech Рыночная капитализация

Что обозначает Рыночная капитализация в Edesa Biotech?

Рыночная капитализация Edesa Biotech, Inc. является $17.44M

Какое определение для Рыночная капитализация?

Рыночная капитализация - это рыночная стоимость в тот момент времени, когда акции, находящиеся в обращении публичной компании, равна цене акций в тот отрезок времени, умноженной на количество акций в обращении .

As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.

Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.

The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.

Что делает Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Компании с рыночная капитализация похож на Edesa Biotech

  • Paramount Gold Nevada Corp имеет Рыночная капитализация из $17.40M
  • Manaksia Aluminium имеет Рыночная капитализация из $17.41M
  • Poddar Housing and Development имеет Рыночная капитализация из $17.41M
  • Odyssey имеет Рыночная капитализация из $17.42M
  • Alkali Metals имеет Рыночная капитализация из $17.43M
  • Alkali Metals имеет Рыночная капитализация из $17.43M
  • Edesa Biotech имеет Рыночная капитализация из $17.44M
  • Monument Mining имеет Рыночная капитализация из $17.45M
  • Surge Copper имеет Рыночная капитализация из $17.45M
  • Security Matters имеет Рыночная капитализация из $17.47M
  • Macarthur Minerals имеет Рыночная капитализация из $17.47M
  • Swiss Water Decaffeinated Coffee имеет Рыночная капитализация из $17.47M
  • Bal Pharma имеет Рыночная капитализация из $17.49M